Rapid and accurate antibody testing on a large scale is key to address the challenges of the COVID-19 pandemic. Over time, SARS-CoV-2 IgG antibodies remain the primary antibodies present.
The Siemens Healthineers SARS-CoV-2 IgG Assay* measures neutralizing IgG antibodies to SARS-CoV-2 in the blood to help clinicians assess the level of an individual's immune response over time.
“Being able to measure a patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection may be useful as we continue to learn more about the virus and what the existence of antibodies may mean. There are still many unknowns about what the presence of SARS-CoV-2 antibodies may tell us about potential immunity, but today’s authorizations give us additional tools to evaluate those antibodies as we continue to research and study this virus.”
Tim Stenzel, M.D., Ph.D., Director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health (read press release)
Results can be produced in as little as 16 minutes on the Dimension® and Dimension Vista® Systems* and 25 minutes on the Atellica® IM Analyzer with a capacity to process up to 440 assays per hour† along with the sensitivity and specificity laboratories have come to expect from us.
SARS-CoV-2 IgG Assay
ADVIA Centaur® XP/XPT
A robust portfolio of reliable antibody tests to detect neutralizing antibodies
We offer the SARS-CoV-2 IgG assay* and the SARS-CoV-2 Total assay for the qualitative and quantitative detection of neutralizing antibodies to the SARS-CoV-2 virus.
A correlation study using a viral neutralizing test demonstrated a strong relationship between index values from the Atellica® IM and ADVIA Centaur® SARS-CoV-2 Total and SARS-CoV-2 IgG assays and neutralizing antibody titers. This allows clinicians to be able to assess and monitor patients’ neutralizing antibody levels. This strong correlation is critical for potential convalescent donor identification as well as future determination of vaccine response and monitoring post-vaccination neutralizing antibody levels.
Comparison of numerical results will help determine how the immune response develops in an individual and persists over time. The combination of these assays provides a more complete picture of a patient’s serological status for the most accurate results throughout his or her continuum of care.